ASCO GI 2025: Practice-Changing Advances in Colorectal Cancer
Three trials presented at ASCO GI 2025 will change practice and improve the treatment of colorectal cancer, according to experts.
Related Articles
2024 Blood Journal Contest
9th Annual Blood Cover Art Contest is now open. In recognition of authors who published in Blood and images used in advancement of science, we…
Emerging Treatment Approaches for HR+/HER2– Early-Stage Breast Cancer
Panelists discuss how emerging treatment strategies, including the use of CDK4/6 inhibitors and personalized risk stratification, are transforming the management of high-risk HR+/HER2– early-stage breast…
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
Alcohol Consumption Does not Modify the Polygenic Risk Score–Based Genetic Risk of Breast Cancer in Postmenopausal Women: Atherosclerosis Risk in Communities Study
Although our findings suggest that alcohol drinking does not modify the PRS-based genetic risk of breast cancer among White and Black women with lower alcohol…
Pertuzumab Biosimilar BLA for HER2+ Breast Cancer Accepted by FDA
After a phase 3 study showed a promising pCR rate with HLX11, the pertuzumab biosimilar’s BLA has been accepted for review by the FDA.
The GATA-3–dependent transcriptome and tumor microenvironment are regulated by eIF4E and XPO1 in T-cell lymphomas
Key PointseIF4E/XPO1 collaboratively transport GATA-3 and GATA-3 targets and are thus therapeutic vulnerabilities in GATA-3–driven TCLs.Impaired eIF4E/XPO1
Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study
PURPOSEApproximately 50% of patients with advanced Merkel cell carcinoma (MCC) have primary or acquired resistance to PD-(L)1 blockade, which may be overcome using combination immune…
Balstilimab Plus Botensilimab Shows Better Response in MSS mCRC
Marwan G. Fakih, MD, discussed the implications of the findings from the phase 2 study for patients with microsatellite stable metastatic colorectal cancer without liver…
